

# API's R&D PORTFOLIO

| PRODUCT NAME                             | THERAPEUTIC CLASS             | CAS nr.      |
|--|-------------------------------|--------------|
| <b>ABACAVIR SULFATE</b>                  | Antiviral (HIV)               | 188062-50-2  |
| <b>ABIRATERONE ACETATE</b>               | Antineoplastic                | 154229-18-2  |
| <b>ACLIDINIUM BROMIDE</b>                | Bronchodilator (COPD)         | 320345-99-1  |
| <b>ALDOXORUBICIN HYDROCHLORIDE</b>       | Antineoplastic                | 1361563-03-2 |
| <b>ALITRETINOIN</b>                      | Antineoplastic; Antipsoriatic | 5300-03-8    |
| ALOGLIPTIN BENZOATE                      | Antidiabetic                  | 850649-62-2  |
| <b>ATAZANAVIR SULFATE</b>                | Antiviral (HIV)               | 229975-97-7  |
| <b>AZACITIDINE</b>                       | Antineoplastic                | 320-67-2     |
| BEXAROTENE                               | Antineoplastic                | 153559-49-0  |
| BLONANSERIN                              | Antipsychotic                 | 132810-10-7  |
| BOSENTAN MONOHYDRATE                     | Antihypertensive              | 157212-55-0  |
| <b>CANGRELOR TETRASODIUM</b>             | Antithrombotic                | 163706-36-3  |
| CERITINIB                                | Antineoplastic                | 1032900-25-6 |
| <b>CLOFARABINE</b>                       | Antineoplastic                | 123318-82-1  |
| COBIMETINIB HEMIFUMARATE                 | Antineoplastic                | 934660-93-2  |
| DANTROLENE SODIUM                        | Antispasmodic                 | 14663-23-1   |
| <b>DAPTOMYCIN</b> (standard and sterile) | Antibacterial                 | 103060-53-3  |
| <b>DECITABINE</b>                        | Antineoplastic                | 2353-33-5    |
| <b>DIHYDROERGOTAMINE MESYLATE</b>        | Antimigraine                  | 6190-39-2    |
| EFINACONAZOLE                            | Antimicrobial                 | 164650-44-6  |
| <b>ENZALUTAMIDE</b>                      | Antineoplastic                | 915087-33-1  |
| <b>ERGOTAMINE</b>                        | Antimigraine                  | 113-15-5     |
| <b>FENRETINIDE</b>                       | Antineoplastic                | 65646-68-6   |
| <b>FIDAXOMICIN</b>                       | Antibiotic                    | 873857-62-6  |
| INDACATEROL MALEATE                      | Bronchodilator                | 753498-25-8  |
| IVABRADINE HYDROCHLORIDE                 | Antianginal                   | 148849-67-6  |
| <b>LENVATINIB MESYLATE</b>               | Antineoplastic                | 857890-39-2  |
| <b>LURASIDONE HYDROCHLORIDE</b>          | Antipsychotic                 | 367514-88-3  |
| <b>NINTEDANIB ESYLATE</b>                | Antineoplastic                | 656247-17-5  |
| <b>OLAPARIB</b>                          | Antineoplastic                | 763113-22-0  |
| <b>OSPEMIFENE</b>                        | Postmenopausal treatment      | 128607-22-7  |
| <b>PITAVASTATIN CALCIUM</b>              | Antilipemic                   | 147526-32-7  |
| <b>POMALIDOMIDE</b>                      | Antineoplastic                | 19171-19-8   |
| PREGABALIN                               | Antiepileptic                 | 148553-50-8  |
| <b>PRISTINAMYCIN</b>                     | Antibacterial                 | 8065-94-9    |
| <b>RALOXIFENE HYDROCHLORIDE</b>          | Antiosteoporotic              | 82640-04-8   |
| <b>RITONAVIR</b> (Form I and II)         | Antiviral (HIV)               | 155213-67-5  |

DISCLAIMER: These APIs are supplied solely: for performing the strictly necessary studies and trials aimed to the obtainment of an AIC or of a marketing authorization, according to Article 10 of directive 2001/83/CE, or for experimental purposes aimed to scientific innovation, or under an agreement or a contract for a co-development aimed to obtain a marketing authorization (dossiers). Any other use that may constitute a violation of any possible related exclusivity rights of the owner(s) of relevant European patents and/or relevant related national patents and/or supplementary protection certificates (SPC), is not allowed. In case of breach of this clause, you will keep us fully indemnified and harmless from any claims and consequences arising out of such use and breach.

PAGE 1 of 2



Olon S.p.A.

Strada Rivoltana km. 6/7 20090 Rodano (Milan) - ITALY  
Phone : +39 02.9523.1 - Fax +39 02.9523.5111 e-mail: [info@olonspa.it](mailto:info@olonspa.it) [www.olonspa.com](http://www.olonspa.com)

| <b>PRODUCT NAME</b>   | <b>THERAPEUTIC CLASS</b>      | <b>CAS nr.</b> |
|---|-------------------------------|----------------|
| <b>ROTIGOTINE</b>   | Anti-Parkinson                | 99755-59-6     |
| RUCAPARIB   | Antineoplastic                | 283173-50-2    |
| TAVABOROLE  | Antimicotic                   | 174671-46-6    |
| <b>TAZAROTENE</b>   | Antipsoriatic; Antiacne       | 118292-40-3    |
| <b>TEICOPLANIN</b>  | Antibacterial                 | 61036-64-4     |
| <b>TERIFLUNOMIDE</b>  | Agents for Multiple Sclerosis | 108605-62-5    |
| <b>THIOTEPA</b>   | Antineoplastic                | 52-24-4        |
| TIOTROPIUM BROMIDE  | Bronchodilator (COPD)         | 136310-93-5    |
| <b>TOFACITINIB CITRATE</b>                                      | Antiarthritic                 | 540737-29-9    |
| <b>TOLVAPTAN</b>  | Diuretic                      | 150683-30-0    |
| UMECLIDINIUM BROMIDE  | Bronchodilator (COPD)         | 869113-09-7    |
| <b>VALGANCICLOVIR HYDROCHLORIDE</b> (amorphous and crystalline) | Antiviral                     | 175865-59-5    |
| VILANTEROL TRIFENATATE  | Bronchodilator (COPD)         | 503070-58-4    |
| <b>VILAZODONE HYDROCHLORIDE</b>                                 | Antidepressant                | 163521-08-2    |
| VILDAGLIPTIN  | Antidiabetic                  | 274901-16-5    |

DISCLAIMER: These APIs are supplied solely: for performing the strictly necessary studies and trials aimed to the obtainment of an AIC or of a marketing authorization, according to Article 10 of directive 2001/83/CE, or for experimental purposes aimed to scientific innovation, or under an agreement or a contract for a co-development aimed to obtain a marketing authorization (dossiers). Any other use that may constitute a violation of any possible related exclusivity rights of the owner(s) of relevant European patents and/or relevant related national patents and/or supplementary protection certificates (SPC), is not allowed. In case of breach of this clause, you will keep us fully indemnified and harmless from any claims and consequences arising out of such use and breach.

